Stockreport

Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights

Passage Bio, Inc.  (PASG) 
PDF Advanced Imagine-1 clinical trial for GM1 gangliosidosis to recruitment of final cohort, Cohort 4, in dose-ascending phase of study following recommendation by Independe [Read more]